Lung cancer study matches drugs to tumor DNA
NCT ID NCT02314481
First seen May 07, 2026 · Last updated May 24, 2026 · Updated 3 times
Summary
This study tested whether giving lung cancer treatments based on the genetic makeup of a person's tumor could improve outcomes. About 50 adults with non-small cell lung cancer that came back after initial treatment received either immunotherapy (atezolizumab) or targeted drugs like vemurafenib or alectinib, depending on their tumor's mutations. The goal was to see how long the cancer stayed under control and to learn which genetic markers predict response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Univeristy College London Hospital
London, United Kingdom
Conditions
Explore the condition pages connected to this study.